Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Compass Therapeutics Inc CMPX

Healthcare Biotechnology
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CMPX)

Compass Therapeutics to Participate in Upcoming December Investor Events

GlobeNewswire November 25, 2025

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2025

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 4, 2025

Compass Therapeutics to Participate in Upcoming November Investor Events

GlobeNewswire November 3, 2025

Compass Therapeutics to Participate in Upcoming September Investor Events

GlobeNewswire August 26, 2025

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

GlobeNewswire August 12, 2025

Compass Therapeutics Announces Proposed Public Offering

GlobeNewswire August 12, 2025

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2025

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

GlobeNewswire August 8, 2025
View More News ››

Opinion & Analysis (NDAQ:CMPX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CMPX)

Buy buddy buy.

Because it's going up today
coolfooldumbguy - April 1, 2025

Buy buddy buy because it's taking off this morning.

This stock is a good buy and position for my portfolio.
coolfooldumbguy - January 28, 2025
View more Bullboard ››

Geekco Technologies Corp.

Geekco Technologies Corp.

Geekco Technologies Corporation, together with its subsidiary, engages in developing and operating mobile applications in ...
View More »